Lung cancer is having a malignant tumor in the lungs especially in the cells lining air passages.
Primary tumor-related signs and symptoms are cough, dyspnea, hemoptysis, and chest discomfort.
Signs and symptoms due to intrathoracic spread may involve the nerves (hoarseness, dyspnea, muscle wasting of upper limb, Horner's syndrome), chest wall and pleura (chest pain, dyspnea) and vascular structures (facial swelling, dilated neck veins, cardiac tamponade) & viscera (dsyphagia).
The signs and symptoms due to metastatic spread are bone pain with or without pleuritic pain, neurologic symptoms, limb weakness, unsteady gait, cervical lymphadenopathy, and skin nodules.
The next-generation TKI* alectinib maintains improvement in lung cancer symptoms for a longer duration than crizotinib, the current standard of care for patients with ALK-positive non-small–cell lung cancer (NSCLC), according to new data from the ALEX** study presented at ELCC 2018.
Hybrid capture-based comprehensive genomic profiling (CGP) may have the capability to detect epidermal growth factor receptor (EGFR) point mutations in non-small cell lung cancer (NSCLC) that were missed by standard-of-care molecular EGFR testing, a recent study found.
Combining the monoclonal antibody targeting PD-L1 atezolizumab and the antiangiogenic biologic bevacizumab with a chemotherapy of carboplatin + paclitaxel (CP) for treating non-squamous metastatic non-small-cell lung cancer (NSCLC) leads to significant improvement in progression-free survival (PFS) compared with bevacizumab + CP as first-line treatment, according to the IMpower150* trial presented at the ESMO Immuno Oncology Congress 2017.
Adding the anti-HGF* antibody ficlatuzumab to the EGFR TKI** gefitinib shows promising antitumour activity and is well tolerated in Asian patients with advanced non-small-cell lung cancer (NSCLC), according to a phase Ib study.
Treatment with the PD-L1* inhibitor durvalumab after chemoradiotherapy significantly prolongs progression-free survival (PFS) by 11 months in patients with locally advanced, unresectable stage III non–small-cell lung cancer (NSCLC), with similar benefits in an Asian subset, according to the PACIFIC** study presented at ESMO Asia 2017 in Singapore.
Osimertinib further extends progression-free survival (PFS) over standard-of-care (SOC) first-line therapy in Asian patients with advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC), according to the Asian subset analysis of the phase III FLAURA* trial.
Indication and demand for genetic testing have increased in recent years, with tests becoming more readily available and affordable, says a leading oncologist at ESMO Asia 2017, highlighting that appreciation of ethical, social, and legal implications of testing and proper test interpretation are important for optimal patient management.
New drug applications approved by US FDA as of 1 - 15 August 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
The use of e-cigarettes changes the innate defence protein profiles in airway secretions, a new study has shown. These changes may lead to questions about e-cigarettes as the supposed healthier alternative to smoking.
Investigators from The University of Hong Kong (HKU) recently identified a mutation in H7N9 virus which causes the virus to possess a higher ability to infect humans while maintaining its ability to circulate effectively in poultry.